Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
News|Videos|June 16, 2024
Petosemtamab (MCLA-158) With Pembrolizumab as First-line (1L) Treatment of Recurrent/Metastatic (r/m) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 2 Study
Author(s)Jérôme Fayette, MD, PhD
Dr. Jérôme Fayette presents the findings of a phase 2 study (NCT03526835) assessing the overall response rate of petosemtamab in combination with pembrolizumab compared to pembrolizumab monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Advertisement
Advertisement
Related to this article
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Five Under 5: Top Oncology Videos for the Week of 9/13
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
The OncFive: Top Oncology Articles for the Week of 9/14/2026
5